Literature DB >> 25744862

Vonoprazan: first global approval.

Karly P Garnock-Jones1.   

Abstract

Vonoprazan (Takecab(®)) is an orally bioavailable potassium-competitive acid blocker (P-CAB) being developed by Takeda for the treatment and prevention of acid-related diseases. The drug is approved in Japan for the treatment of acid-related diseases, including erosive oesophagitis, gastric ulcer, duodenal ulcer, peptic ulcer, gastro-oesophageal reflux, reflux oesophagitis and Helicobacter pylori eradication. Phase III development is underway for the prevention of recurrence of duodenal and gastric ulcer in patients receiving aspirin or NSAID therapy. Phase I development was conducted in the UK for gastro-oesophageal reflux; however, no further development has been reported. This article summarizes the milestones in the development of vonoprazan leading to this first approval for acid-related diseases.

Entities:  

Mesh：

Substances：

Year:  2015        PMID： 25744862     DOI： 10.1007/s40265-015-0368-z

Source DB:  PubMed          Journal:  Drugs        ISSN： 0012-6667            Impact factor:   9.546


  5 in total

1.  1-[5-(2-Fluorophenyl)-1-(pyridin-3-ylsulfonyl)-1H-pyrrol-3-yl]-N-methylmethanamine monofumarate (TAK-438), a novel and potent potassium-competitive acid blocker for the treatment of acid-related diseases.

Authors:  Yasunobu Hori; Akio Imanishi; Jun Matsukawa; Yasuhiro Tsukimi; Haruyuki Nishida; Yasuyoshi Arikawa; Keizo Hirase; Masahiro Kajino; Nobuhiro Inatomi
Journal:  J Pharmacol Exp Ther       Date:  2010-07-12       Impact factor: 4.030

2.  Characterization of a novel potassium-competitive acid blocker of the gastric H,K-ATPase, 1-[5-(2-fluorophenyl)-1-(pyridin-3-ylsulfonyl)-1H-pyrrol-3-yl]-N-methylmethanamine monofumarate (TAK-438).

Authors:  Jai Moo Shin; Nobuhiro Inatomi; Keith Munson; David Strugatsky; Elmira Tokhtaeva; Olga Vagin; George Sachs
Journal:  J Pharmacol Exp Ther       Date:  2011-08-09       Impact factor: 4.030

3.  Discovery of a novel pyrrole derivative 1-[5-(2-fluorophenyl)-1-(pyridin-3-ylsulfonyl)-1H-pyrrol-3-yl]-N-methylmethanamine fumarate (TAK-438) as a potassium-competitive acid blocker (P-CAB).

Authors:  Yasuyoshi Arikawa; Haruyuki Nishida; Osamu Kurasawa; Atsushi Hasuoka; Keizo Hirase; Nobuhiro Inatomi; Yasunobu Hori; Jun Matsukawa; Akio Imanishi; Mitsuyo Kondo; Naoki Tarui; Teruki Hamada; Terufumi Takagi; Toshiyuki Takeuchi; Masahiro Kajino
Journal:  J Med Chem       Date:  2012-04-30       Impact factor: 7.446

4.  Novel approaches to inhibition of gastric acid secretion.

Authors:  George Sachs; Jai Moo Shin; Richard Hunt
Journal:  Curr Gastroenterol Rep       Date:  2010-12

5.  Protonated form: the potent form of potassium-competitive acid blockers.

Authors:  Hua-Jun Luo; Wei-Qiao Deng; Kun Zou
Journal:  PLoS One       Date:  2014-05-20       Impact factor: 3.240
  5 in total
  24 in total

Review 1.  Vonoprazan: A Novel and Potent Alternative in the Treatment of Acid-Related Diseases.

Authors:  Xiaoxiao Yang; Yueyue Li; Yiyuan Sun; Mingming Zhang; Chuanguo Guo; Iqtida Ahmed Mirza; Yan-Qing Li
Journal:  Dig Dis Sci       Date:  2017-12-27       Impact factor: 3.199

2.  The binding selectivity of vonoprazan (TAK-438) to the gastric H+, K+ -ATPase.

Authors:  D R Scott; K B Munson; E A Marcus; N W G Lambrecht; G Sachs
Journal:  Aliment Pharmacol Ther       Date:  2015-09-30       Impact factor: 8.171

Review 3.  Vonoprazan-based therapy for Helicobacter pylori eradication: experience and clinical evidence.

Authors:  Yuko Akazawa; Daisuke Fukuda; Yutaka Fukuda
Journal:  Therap Adv Gastroenterol       Date:  2016-09-22       Impact factor: 4.409

Review 4.  A narrative review of postoperative bleeding in patients with gastric cancer treated with endoscopic submucosal dissection.

Authors:  Li Liu; Hongqun Liu; Zhijie Feng
Journal:  J Gastrointest Oncol       Date:  2022-02

5.  Effects of Simvastatin on the Metabolism of Vonoprazan in Rats Both in vitro and in vivo.

Authors:  Yun Hong; Da-Peng Dai; Jian-Ping Cai; Shuang-Hu Wang; Yi-Ran Wang; Fang-Ling Zhao; Shan Zhou; Quan Zhou; Pei-Wu Geng; Yun-Fang Zhou; Xue Xu; Ji-Hua Shi; Qing-Feng Luo
Journal:  Drug Des Devel Ther       Date:  2022-06-09       Impact factor: 4.319

Review 6.  Efficacy, safety and cost-effectiveness of vonoprazan vs Proton Pump Inhibitors in reflux disorders and H. pylori eradication: A literature review.

Authors:  Muhammad Shehryar; Rana Uzair Ahmad; Hira Khalid Kareem; Laiba Khan; Muhammad Fawad Ashraf; Ahtizaz Hassan; Sabeena Saeed; Haseeb Khan Tareen; Dr Adnan Nazir; Muhammad Aizaz Ashraf
Journal:  Ann Med Surg (Lond)       Date:  2022-09-22

Review 7.  The First-in-Class Potassium-Competitive Acid Blocker, Vonoprazan Fumarate: Pharmacokinetic and Pharmacodynamic Considerations.

Authors:  Hirotoshi Echizen
Journal:  Clin Pharmacokinet       Date:  2016-04       Impact factor: 6.447

Review 8.  Potent Acid Suppression with PPIs and P-CABs: What's New?

Authors:  Richard H Hunt; Carmelo Scarpignato
Journal:  Curr Treat Options Gastroenterol       Date:  2018-12

9.  Safety and efficacy of Vonoprazan-based triple therapy against Helicobacter pylori infection: A single-center experience with 1118 patients.

Authors:  Daisuke Fukuda; Yuko Akazawa; Fuminao Takeshima; Kazuhiko Nakao; Yutaka Fukuda
Journal:  Therap Adv Gastroenterol       Date:  2016-06-20       Impact factor: 4.409

Review 10.  Potassium Channelopathies and Gastrointestinal Ulceration.

Authors:  Jaeyong Han; Seung Hun Lee; Gerhard Giebisch; Tong Wang
Journal:  Gut Liver       Date:  2016-11-15       Impact factor: 4.519
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.